Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252-Reference-Cited by-同舟云学术

Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252

Published:2005-12 Issue:5 Volume:6 Page:425-432
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Perez Edith A.,Suman Vera J.,Rowland Kendrith M.,Ingle James N.,Salim Muhammad,Loprinzi Charles L.,Flynn Patrick J.,Mailliard James A.,Kardinal Carl G.,Krook James E.,Thrower Abby R.,Visscher Daniel W.,Jenkins Robert B.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Results of two openlabel, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer;Pegram;J Natl Cancer Inst,2004

2. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer;Burris;J Clin Oncol,2004

3. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients wtih HER-2/neu positive advanced breast cancer;Robert;Breast Cancer Res Treat,2002

4. Carboplatin dosage: prospective evaluation of a simple formula based on renal function;Calvert;J Clin Oncol,1989

5. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma;Perez;Cancer,2000

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-07

2. Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer;Journal of Drug Delivery Science and Technology;2024-03

3. Unraveling the Impact of Aberrant Splicing Machinery on Drug Resistance in Breast Cancer: Identifying Targets for Innovative Counteractive Strategies;Overcoming Breast Cancer Therapy Resistance;2024

4. Margetuximab in HER2-positive metastatic breast cancer;Future Oncology;2023-05

5. Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations;Journal of Oncology Pharmacy Practice;2022-08-15